1. [Perception of pT1a,b pN0 breast tumor prognosis by the French oncology community: Results of the EURISTIC national survey]
- Author
-
Spielmann, Marc, Dalenc, Florence, Pointreau, Yoann, Azria, David, Classe, Jean-Marc, Dromain, Clarisse, Facchini, Thomas, Gonçalves, Anthony, Liegeois, Philippe, Namer, Moïse, Pivot, Xavier, Vincent-Salomon, Anne, Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR), Institut Claudius Regaud, Clinique Victor Hugo [Le Mans], Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), Département de radiothérapie, CRLCC Val d'Aurelle - Paul Lamarque, Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), UNICANCER, Polyclinique Courlancy (PC), Polyclinique de Courlancy, Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Service d'Oncologie Médicale [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Institut Curie [Paris], and Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)
- Subjects
PT1a/b pN0 ,MESH: Ki-67 Antigen ,MESH: Tumor Burden ,Receptor, ErbB-2 ,Embolism ,Breast Neoplasms ,Triple Negative Breast Neoplasms ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Medical Oncology ,MESH: Perception ,MESH: Prognosis ,Breast cancer ,Surveys and Questionnaires ,Mitotic Index ,Pronostic ,Humans ,MESH: Surveys and Questionnaires ,Cancer du sein ,MESH: Medical Oncology ,MESH: Mitotic Index ,MESH: Age Factors ,MESH: Humans ,Age Factors ,MESH: Triple Negative Breast Neoplasms ,Prognosis ,Tumor Burden ,MESH: Receptor, ErbB-2 ,MESH: France ,Ki-67 Antigen ,Receptors, Estrogen ,MESH: Receptors, Estrogen ,Female ,Perception ,France ,MESH: Female ,MESH: Breast Neoplasms ,MESH: Embolism ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology - Abstract
International audience; The prognosis of infracentimetric breast cancers (BC) is heterogeneous. The EURISTIC survey describes how French oncology specialists perceive the prognosis of pT1a,b pN0 BCs. A self-administered questionnaire has been sent to over 2000 French BC specialists. Six hundred and sixty-three physicians responded. Fifty-eight percent do not consider tumor size as a key prognostic criterion. They consider that the cutoff for poor prognosis is 22mm, 10mm and 7mm for hormone receptors (HRs)+, HER2+ and triple-negative (TN) tumors respectively. Eighty-three percent of respondents consider that a HR+ pT1a,b tumor has a good prognosis (21% and 8% for HER2+ and TN respectively). Factors perceived as most detrimental are: HER2 overexpression (29% of respondents); HR- (20%); high grade (20%); TN status (14%); high KI67 (5%); presence of lymphovascular invasion (3%); young age (2%) and high mitotic index (1%). For French specialists, immunohistochemical characteristics, in particular hormone and HER2 status, are strong prognostic factors in BCs below 1cm.
- Published
- 2016
- Full Text
- View/download PDF